APPLICATION OF BOTULINUM TOXIN IN CONSERVATIVE TREATMENT OF MASTICATORY MUSCLES DYSFUNCTION
DOI:
https://doi.org/10.35120/medisij030201mKeywords:
botulinum toxin, neuromodulator, TMJ, bruxismAbstract
The purpose of this paper is to describe the application of the botulinum toxin in diseases of the temporomandibular system of a muscular type such as masticatory hypertrophy, spasm, bruxism, and tension headaches of idiopathic etiology. The masticatory system is a complex apparatus with great adaptive capacity. Still, when that capacity is exceeded, functional disorders occur followed by a series of symptoms that depend on individual, local, and systemic etiological factors. Occlusal trauma exceeding the physiological limits of the teeth, periodontium, and TMJ leads to a series of functional disorders. Temporomandibular dysfunctions (TMD) are used to describe a large, heterogeneous group of diseases of the temporomandibular joint (TMJ) and its adjacent tissues and organs. Botulinum toxin type A, hemagglutinin complex with 500 IU (DISPORT Ipsen Biopharm, UK) was used for the therapy of muscle disorders like bruxism or night teeth clenching in female patient 26 years old. Depending on the dose that was applied to the targeted muscle, a complete or partial reduction in contraction occurs with reduced function and weakening of the muscle. Two weeks after applying the neuromodulator, the patient reported a reduction in pain and episodes of teeth grinding and clenching. Bilateral hypotrophy of left and right masseter muscles was noticeable after 2 months. We concluded that botulinum toxin could be used as an effective treatment for reducing nocturnal bruxism and myofascial pain in patients with bruxism.
Downloads
References
Almukhtar RM, Fabi SG. (2019). The masseter muscle and its role in facial contouring, aging, and quality of life: a literature review. Plast Reconstr Surg. 143(1):39e-48e.
Baek SM, Baek RM, Shin MS. (1994). Refinement in aesthetic contouring of the prominent mandibular angle. Aesthetic Plast Surg. 18(3):283-9.
Barker D. K. (2004). Occlusal interferences and temporomandibular dysfunction. General dentistry, 52(1), 56–62. Beckers HL. (1977). Masseteric muscle hypertrophy and its intraoral surgical correction. Journal of Maxillofacial Surgery.5: 28-35.
Gholampour S., Gholampour H., Khanmohammadi H. (2019). Finite element analysis of occlusal splint therapy in patients with bruxism. BMC Oral Health. 19(1) J. Ahlgren, K.-Å. Omnell, B. Sonesson, N.G. Toremalm; Bruxism and Hypertrophy of the Masseter Muscle: A Clinical, Morphological and Functional Investigation. Practica Oto-Rhino-Laryngologica 1 January (1969) 31 (1): 22–29. Kebede B, Megersa S. (2011). Idiopathic masseter muscle hypertrophy. Ethiop J Health Sci. 21(3):209-12. Klasser GD, N Rei, GJ Lavigne. (2015). Sleep Bruxism Etiology: The Evolution of a Changing Paradigm. J Can Dent Assoc. 81:f2
Kapusevska B. (2014). Бруксизам и оклузални парафункции: општ дел. Скопје, Стоматолошки Факултет,
Lee CJ, Kim SG, Kim YJ, et al. (2007). Electrophysiology change and facial contour following botulinum toxin injections in square faces. Plast Reconstr Surg. 120:769-78.
Manfredini D, Lobbezoo F. Role of psychosocial factors in the etiology of bruxism. J Orofac Pain 2009; 23(2):153-66.
Moore AP, Wood GD. (1994). The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 32:26-8.
Ommerborn, M. A., Schneider, C., Giraki, M., Schäfer, R., Handschel, J., Franz, M., & Raab, W. H. (2007). Effects of an occlusal splint compared with cognitive-behavioral treatment on sleep bruxism activity. European journal of oral sciences, 115(1), 7–14.
Raluca A, D Raluca, A Dragomir, C Ilie, et al. (2020). The use of botulinum toxin in the management of bruxism and facial arthromyalgia syndrome. Romanian Journal of Medical Practice 15(1):77-81
Sleep related bruxism. In: International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
Shim YJ, Lee HJ, Park KJ, et al. (2020). Botulinum toxin therapy for managing sleep bruxism: a randomized and placebocontrolled trial. Toxins (Basel).12(3):168.
Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. (2000). JADA.131:211-6.
Tsukiyama Y, Baba K, Clark GT. (2001). An evidence-bases assessment of occlusal adjustment as a treatment for temporomandibular disorders. J Prosthet Dent. 86:57-66.
Van der Glas, H. W., Buchner, R., & van Grootel, R. J. (2000). Comparison of treatment options for myogenous temporomandibular dysfunction]. Nederlands tijdschrift voor tandheelkunde, 107(12), 505–512.